-
Leveraging Alcon’s strong business capabilities and assets to drive additional development and entry to Rocklatan and Rhopressa
-
Acquisition provides pharmaceutical analysis and improvement capabilities and additional experience for future product pipeline
-
Expands Alcon’s presence within the $20 billion world ophthalmic pharmaceutical class1
GENEVA, November 22, 2022–(BUSINESS WIRE)–Regulatory Information:
Alcon (SIX/NYSE: ALC), the worldwide chief in eye care devoted to serving to individuals see brilliantly, at this time introduced that it has accomplished its acquisition of Aerie Prescription drugs, Inc. (NASDAQ: AERI, “Aerie”). This transaction helps bolster Alcon’s presence within the ophthalmic pharmaceutical house with its rising portfolio of business merchandise and improvement pipeline.
“As we welcome the Aerie staff to Alcon, we sit up for leveraging our increasing business footprint and experience to convey Rocklatan® and Rhopressa® to much more prospects and their sufferers,” stated David Endicott, CEO of Alcon. “Alcon has a wealthy historical past within the ophthalmic pharmaceutical house rooted in a deep understanding of Eye Care Professionals. We’re excited so as to add Aerie’s vital technical experience to Alcon R&D, which reinforces our efforts to construct a compelling portfolio of ophthalmic prescription drugs.”
By means of the transaction, Alcon has added the business merchandise Rocklatan (netarsudil and latanoprost ophthalmic answer) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic answer) 0.02%, in addition to AR-15512, a Section 3 product candidate for dry eye illness. Alcon has additionally acquired a pipeline of ophthalmic pharmaceutical product candidates with the chance to leverage Aerie’s current analysis and improvement capabilities.
The transaction enhances Alcon’s growth into the ophthalmic pharmaceutical house, together with acquisitions of the unique U.S. commercialization rights for Simbrinza® from Novartis in April 2021 and Eysuvis® and Inveltys® from Kala Prescription drugs, Inc. in Could 2022.
Alcon intends to totally combine Aerie into its enterprise. As beforehand disclosed, the Firm has used debt to fund the transaction for a complete buy consideration of roughly $930 million.
J.P. Morgan acted as Alcon’s monetary advisor for the transaction, and Alcon’s authorized advisor was Skadden, Arps, Slate, Meagher & Flom LLP. Goldman Sachs & Co. LLC and Lazard acted as Aerie’s monetary advisors for the transaction, and Aerie’s authorized advisor was Fried, Frank, Harris, Shriver & Jacobson LLP.
About Alcon
Alcon helps individuals see brilliantly. As the worldwide chief in eye care with a heritage spanning over 75 years, we provide the broadest portfolio of merchandise to reinforce sight and enhance individuals’s lives. Our Surgical and Imaginative and prescient Care merchandise contact the lives of greater than 260 million individuals in over 140 international locations every year dwelling with circumstances like cataracts, glaucoma, retinal illnesses and refractive errors. Our greater than 24,000 associates are enhancing the standard of life by way of revolutionary merchandise, partnerships with Eye Care Professionals and applications that advance entry to high quality eye care. Study extra at www.alcon.com.
References
-
Ophthalmology Medicine International Market Report 2021: COVID-19 Influence and Restoration to 2030.
Cautionary Word Concerning Ahead-Trying Statements
This press launch incorporates sure “forward-looking statements” inside the which means of the protected harbor provisions of the US Non-public Securities Litigation Reform Act of 1995. Ahead-looking statements might be recognized by phrases resembling “anticipate,” “intend,” “dedication,” “look ahead,” “preserve,” “plan,” “objective,” “search,” “goal,” “assume,” “consider,” “challenge,” “estimate,” “count on,” “technique,” “future,” “doubtless,” “could,” “ought to,” “will” and related references to future intervals. Examples of forward-looking statements embody, amongst others, statements we make concerning our liquidity, income, gross margin, working margin, efficient tax charge, overseas forex trade actions, earnings per share, our plans and selections relating to numerous capital expenditures, capital allocation priorities and different discretionary objects such because the transformation program, market development assumptions, our acquisition of Aerie, and customarily, our expectations regarding our future efficiency and the results of the COVID-19 pandemic on our companies.
Ahead-looking statements are neither historic information nor assurances of future efficiency. As a substitute, they’re primarily based solely on our present beliefs, expectations and assumptions concerning the way forward for our enterprise, future plans and techniques, and different future circumstances. As a result of forward-looking statements relate to the longer term, they’re topic to inherent uncertainties and dangers which might be tough to foretell resembling: cybersecurity breaches or different disruptions of our info know-how programs; compliance with knowledge privateness, id safety and knowledge safety legal guidelines; our skill to adjust to the US International Corrupt Practices Act of 1977 and different relevant anti-corruption legal guidelines, significantly provided that we have now entered right into a three-year Deferred Prosecution Settlement with the U.S. Division of Justice; our success in finishing and integrating strategic acquisitions; our skill to execute and obtain the anticipated advantages of our transformation program; anticipated tax remedy, unexpected liabilities, future capital expenditures, revenues, bills, earnings, synergies, financial efficiency, indebtedness, monetary situation, losses, future prospects, and enterprise and administration methods for the Aerie transaction; transaction prices of the Aerie transaction; the impression of a disruption in our world provide chain or essential services; the impact of the COVID-19 pandemic in addition to different viral or illness outbreaks; world and regional financial, monetary, authorized, tax, political and social change; Russia’s conflict on Ukraine and the ensuing world response; the business success of our merchandise and our skill to keep up and strengthen our place in our markets; the success of our analysis and improvement efforts, together with our skill to innovate to compete successfully; pricing strain from adjustments in third celebration payor protection and reimbursement methodologies; ongoing business consolidation; our skill to correctly educate and practice healthcare suppliers on our merchandise; the impression of unauthorized importation of our merchandise from international locations with decrease costs to international locations with larger costs; our reliance on outsourcing key enterprise capabilities; adjustments in stock ranges or shopping for patterns of our prospects; our skill to draw and retain certified personnel; our skill to service our debt obligations; the necessity for extra financing by way of the issuance of debt or fairness; our skill to guard our mental property; the results of litigation, together with product legal responsibility lawsuits and governmental investigations; our skill to adjust to all legal guidelines to which we could also be topic; impact of product remembers or voluntary market withdrawals; the implementation of our enterprise useful resource planning system; the accuracy of our accounting estimates and assumptions, together with pension and different post-employment profit plan obligations and the carrying worth of intangible property; the flexibility to acquire regulatory clearance and approval of our merchandise in addition to compliance with any post-approval obligations, together with high quality management of our manufacturing; legislative, tax and regulatory reform; the flexibility of Alcon Prescription drugs Ltd. to adjust to its funding tax incentive settlement with the Swiss State Secretariat for Financial Affairs in Switzerland and the Canton of Fribourg, Switzerland; our skill to handle environmental, social and governance issues to the satisfaction of our many stakeholders, a few of which can have competing pursuits; the impression of being listed on two inventory exchanges; the flexibility to declare and pay dividends; the totally different rights afforded to our shareholders as a Swiss company in comparison with a U.S. company; and the impact of sustaining or shedding our overseas personal issuer standing underneath U.S. securities legal guidelines.
Further elements are mentioned in our filings with america Securities and Alternate Fee, together with our Kind 20-F. Ought to a number of of those uncertainties or dangers materialize, or ought to underlying assumptions show incorrect, precise outcomes could fluctuate materially from these anticipated. Due to this fact, you shouldn’t depend on any of those forward-looking statements. Ahead-looking statements on this press launch converse solely as of the date of its submitting, and we assume no obligation to replace forward-looking statements on account of new info, future occasions or in any other case.
Join with us on
Facebook
LinkedIn
View supply model on businesswire.com: https://www.businesswire.com/news/home/20221121005924/en/
Contacts
Investor Relations
Allen Trang
+ 41 589 112 110 (Geneva)
+ 1 817 615 2789 (Fort Value)
investor.relations@alcon.com
Media Relations
Steven Smith
+ 41 589 112 111 (Geneva)
+ 1 817 551 8057 (Fort Value)
globalmedia.relations@alcon.com
